Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

What is your preferred first line therapy for metastatic sarcomatoid renal cell carcinoma?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Vanderbilt-Ingram Cancer Center

Sarcomatoid RCC is a heterogeneous and difficult disease. Arising across all histologies, it generally portends a worse prognosis. VEGF TKIs have activity and I think are the default standard of care, but outcomes are suboptimal. Chemotherapy regimens have been tried with limited success, although I...

How would you proceed after complete response to carboplatin/paclitaxel/bevacizumab in a patient who presented with distantly recurrent SCC of the cervix?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Legacy Health System

I favor treating this patient in accordance with patients on GOG 240 where the patients were treated until disease progression, unacceptable toxicity, or complete response. In this pivotal prospective study, combination platinum doublets with bevacizumab were shown to have high response rates, compl...

Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Warren Alpert Medical School of Brown University

Given the potential benefits of the addition of pembrolizumab to neoadjuvant chemotherapy in clinical stage IIB-III TNBC, I would favor doing so [but not for clinical stage I or small IIA (T<3 cm N0), in whom the potential benefits would be more modest], but I would monitor the patient closely for a...

Would you use fezolinetant for hot flashes for men on ADT?

5
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

I might consider it after trying the usual agents that will at least partially relieve symptoms in the majority of patients, such as low-dose megestrol or venlafaxine (there are others, but these are the ones with which I have had the most experience and success). Fezolinetant is expensive and requi...

When do you consider the addition of concurrent pembrolizumab to breast irradiation?

6
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · New York University School of Medicine

With the publication of KEYNOTE-522 (Schmid et al., PMID 32101663), we are seeing this scenario much more frequently as patients continue the pembrolizumab in the adjuvant setting.A post-hoc analysis of the timing of radiation in the KEYNOTE-522 trial was presented in abstract form at SABCS 2022, (P...

How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · City of Hope Orange County

In the guidelines, the fully humanized version of panitumumab can be used interchangeably where cetuximab is indicated for patients with colorectal cancer.The anaphylactic reactions are not uncommon, going back to the homology with the tick bite story.Chung et al., PMID 18337601I have encountered pu...

Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?

7
3 Answers

Mednet Member
Mednet Member
Pulmonology · Northwestern University Feinberg School of Medicine

I agree that incidence is low, but estimates for radiographically occult nodal disease range from 10-20% and the fact is there isn't great literature on this. A PET scan is a decent test, better than a regular CT, but there are still a significant minority of patients that are mis-staged when an EBU...

What are your top takeaways in GU Cancers from ASCO 2024?

6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

PSMAfore presented previously showed (177Lu-PSMA-617) prolonged radiographic progression-free survival vs change of androgen receptor pathway inhibitor (ARPI) in taxane-naïve patients with metastatic castration-resistant prostate cancer. At ASCO, data presented showed 177Lu-PSMA-617 delayed time to ...

What is the appropriate timeline to start post mastectomy chest wall/regional nodal XRT (+/- reconstruction) after surgery?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

If the patient received neoadjuvant chemotherapy, we typically give RT prior to additional chemotherapy (ex. xeloda for triple negative with residual, TDM1 for HER2+ with residual) and try to start 4-6 weeks post-op given that they are well healed and/or reconstruction/expanders completely filled. I...

In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

In the case of imaging CR, I delineate CTVp based on pre-chemo volumes and apply PTV margin. If less than CR, I use post-chemo volumes to delineate GTVp and then utilize 4DCT to construct ITVp followed by appropriate CTV and PTV margins. Both approaches are consistent with ESTRO ACROP guidelines pub...